TASIMELTEON

Search structure


Trade Names:	HETLIOZ
Synonyms:	BMS-214,778 BMS-214778 HETLIOZ HETLIOZ LQ VEC-162
Status:	Approved (2014)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	N05CH03
UNII:	SHS4PU80D9

Structure


InChI Key	PTOIAAWZLUQTIO-GXFFZTMASA-N
Smile	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2
InChI	InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H19NO2
Molecular Weight	245.32
AlogP	2.25
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	38.33
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	18.0

Pharmacology

Action	Mechanism of Action	Reference
AGONIST	Melatonin receptor agonist

	Primary Target
MT₁ receptor
MT₂ receptor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	-	-	-
Enzyme Transferase	-	-	-	-	1.176-7.34
Enzyme	-	-	-	-	1.176-7.34
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-8.79--4.11
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine-derivative receptor (family A GPCR) Melatonin receptor	-	-	-	0.07	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Smith-Magenis Syndrome	4	D058496	ClinicalTrials
Sleep Wake Disorders	4	D012893	ClinicalTrials
Sleep Initiation and Maintenance Disorders	3	D007319	ClinicalTrials
Depressive Disorder, Major	2	D003865	ClinicalTrials
REM Sleep Behavior Disorder	1	D020187	ClinicalTrials
Kidney Diseases	1	D007674	ClinicalTrials
Liver Diseases	1	D008107	ClinicalTrials

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	17.0
Nervous system disorders Abnormal dreams	10.0
Investigations Alanine aminotransferase increased	10.0
Psychiatric disorders Nightmare	10.0
Nervous system disorders Headache
Infections and infestations Upper respiratory tract infection	7.0
Infections and infestations Urinary tract infection	7.0
Investigations Alanine aminotransferase increased
Infections and infestations Urinary tract infection

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Nervous system disorders	22.74
Psychiatric disorders	22.3
General disorders and administration site conditions	20.52
Injury, poisoning and procedural complications	5.49
Gastrointestinal disorders	5.1
Respiratory, thoracic and mediastinal disorders	4.2
Infections and infestations	2.87
Vascular disorders	2.27
Cardiac disorders	2.23
Musculoskeletal and connective tissue disorders	2.11

Cross References

Resources	Reference
CAS NUMBER	609799-22-6
ChEBI	79042
ChEMBL	CHEMBL2103822
DrugBank	DB09071
DrugCentral	4820
EPA CompTox	DTXSID70209826
FDA SRS	SHS4PU80D9
Guide to Pharmacology	7393
PubChem	10220503
SureChEMBL	SCHEMBL3505912
ZINC	ZINC000004392649

CONTENTS